RxDoctor Payments Data

Cassidy Hood, MD

Family Medicine · Greenville, SCNPI 1518319490

Payments from drug & device makers

$1,763in general payments, 2019–2025

Across 72 payments — averaging $24.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$980
  • Novo Nordisk$349
  • AstraZeneca$238
  • Lilly USA, LLC$77
  • Takeda Pharmaceuticals U.S.A., Inc.$26
  • Adlon Therapeutics L.p.$16
  • plus $77 from 6 others

What the payments were for

  • Food & beverage$1,763100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,763 in reported general payments places this provider in the 70th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$100,384
Medicare patients
284
Services billed
2,786

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$87,338
JardianceEmpagliflozin50$57,065
EliquisApixaban31$44,471
MounjaroTirzepatide17$33,021
FarxigaDapagliflozin Propanediol36$32,295
Breztri AerosphereBudesonide/Glycopyr/Formoterol44$27,261
JanuviaSitagliptin Phosphate16$17,854
LinzessLinaclotide12$13,742
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$6,899
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen155$3,799
Albuterol Sulfate HfaAlbuterol Sulfate108$3,425
Atorvastatin Calcium239$2,437
Gabapentin176$2,395
Novolog FlexpenInsulin Aspart14$2,384
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$349$87,33875 claims
AstraZenecaFarxiga, Breztri Aerosphere$238$59,55680 claims
Boehringer IngelheimJardiance$12$57,06550 claims
Lilly USA, LLCMounjaro$77$33,02117 claims
MerckJanuvia$12$17,85416 claims
AbbVieLinzess, Synthroid$980$14,74134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →